Across TCGA pan-cancer cohorts, RNA5SP516 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNA5SP516 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNA5SP516 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNA5SP516 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.
LIHC, COAD, and OV are the cancer types where RNA5SP516 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.